Synferon
    42.
    发明授权
    Synferon 失效

    公开(公告)号:US06548063B1

    公开(公告)日:2003-04-15

    申请号:US09604073

    申请日:2000-06-27

    IPC分类号: A61K39395

    摘要: The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon polypeptide, called “Synferon”. Synferon polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Synferon activity. Also provided are therapeutic methods for treating immune system-related disorders.

    摘要翻译: 本发明涉及作为干扰素家族成员的新型Synferon蛋白。 特别地,提供了分离的核酸分子,其编码称为“Synferon”的合成干扰素多肽。 还提供了Synferon多肽,载体,宿主细胞以及用于制备它的重组方法。 本发明还涉及用于鉴定Synferon活性的激动剂和拮抗剂的筛选方法。 还提供了治疗免疫系统相关疾病的治疗方法。

    Synferon, a synthetic interferon
    44.
    发明授权
    Synferon, a synthetic interferon 失效
    Synferon,一种合成的干扰素

    公开(公告)号:US6114145A

    公开(公告)日:2000-09-05

    申请号:US205264

    申请日:1998-12-02

    摘要: The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon polypeptide, called "Synferon". Synferon polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Synferon activity. Also provided are therapeutic methods for treating immune system-related disorders.

    摘要翻译: 本发明涉及作为干扰素家族成员的新型Synferon蛋白。 特别地,提供了分离的核酸分子,其编码称为“Synferon”的合成干扰素多肽。 还提供了Synferon多肽,载体,宿主细胞以及用于制备它的重组方法。 本发明还涉及用于鉴定Synferon活性的激动剂和拮抗剂的筛选方法。 还提供了治疗免疫系统相关疾病的治疗方法。

    Human stanniocalcin-alpha
    47.
    发明授权
    Human stanniocalcin-alpha 失效
    人类猕猴桃

    公开(公告)号:US06955885B2

    公开(公告)日:2005-10-18

    申请号:US10418226

    申请日:2003-04-18

    CPC分类号: C07H21/04 C07K14/575

    摘要: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalances which can lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use in the regulation of electrolyte imbalances which can lead to hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha sequences is also disclosed.

    摘要翻译: 公开了一种编码这种多肽的人类猕猴素α多肽和DNA(RNA),以及通过重组技术产生此类多肽的方法。 还公开了利用这种多肽来调节可导致肾,骨和心脏病以及骨质疏松症和佩吉特氏病的电解质不平衡的方法。 还公开了抗这些多肽的拮抗剂及其在调节可导致低钙血症和骨质疏松症的电解质不平衡中的用途。 还公开了将斯诺钙钙素α序列用作诊断疾病或与突变形式的锡氨钙素-α序列相关的疾病的易感性的用途。

    Extracellular/epidermal growth factor-like protein
    48.
    发明授权
    Extracellular/epidermal growth factor-like protein 失效
    细胞外/表皮生长因子样蛋白

    公开(公告)号:US06852506B1

    公开(公告)日:2005-02-08

    申请号:US08839525

    申请日:1997-04-11

    CPC分类号: C07K14/485

    摘要: The present invention discloses an extracellular/epidermal growth factor polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include induction of DNA synthesis, stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.

    摘要翻译: 本发明公开了细胞外/表皮生长因子多肽和编码这些多肽的多核苷酸。 还提供了通过重组技术和多肽的治疗用途产生此类多肽的方法,其包括诱导DNA合成,刺激伤口愈合,治疗神经障碍,治疗眼部疾病,治疗肾脏和肝脏疾病以及刺激胚胎发生和血管发生。 还公开了抗这种多肽的拮抗剂及其作为治疗瘤形成的治疗剂的用途。 还公开了用于检测本发明多肽的改变水平的诊断测定和编码本发明多肽的核酸序列中的突变。

    Chemokine &agr;-4
    49.
    发明授权
    Chemokine &agr;-4 失效
    趋化因子α-4

    公开(公告)号:US06576445B1

    公开(公告)日:2003-06-10

    申请号:US09630709

    申请日:2000-08-01

    IPC分类号: C12P2106

    CPC分类号: C07K14/522 A61K38/00

    摘要: The present invention relates to a novel CK&agr;-4 protein which is a member of the CXC chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK&agr;-4 protein. CK&agr;-4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK&agr;-4 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

    摘要翻译: 本发明涉及作为CXC趋化因子家族成员的新型CKalpha-4蛋白。 特别地,提供编码人CKalpha-4蛋白的分离的核酸分子。 也提供CKalpha-4多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及鉴定CKalpha-4活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测免疫系统相关疾病的诊断方法和用于治疗免疫系统相关疾病的治疗方法。

    Polynucleotides encoding chemokine &bgr;-6 antagonists
    50.
    发明授权
    Polynucleotides encoding chemokine &bgr;-6 antagonists 失效
    编码趋化因子β-6拮抗剂的多核苷酸

    公开(公告)号:US06379926B1

    公开(公告)日:2002-04-30

    申请号:US09419281

    申请日:1999-10-15

    IPC分类号: C12N121

    摘要: Human chemokine &bgr;-6 agonist and antagonist polypeptides and DNA encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. The chemokine &bgr;-6 antagonists of the present invention may be employed to treat rheumatoid arthritis, lung inflammation, allergy, asmtha, infectious diseases and to prevent inflammation and atherosclerosis. The chemokine &bgr;-6 agonists may be employed to myeloprotect patients undergoing chemotherapy.

    摘要翻译: 公开了人类趋化因子β-6激动剂和拮抗剂多肽以及编码这些多肽的DNA以及通过重组技术产生此类多肽的方法。 本发明的趋化因子β-6拮抗剂可用于治疗类风湿性关节炎,肺部炎症,过敏,甲状腺炎,感染性疾病和预防炎症和动脉粥样硬化。 趋化因子β-6激动剂可用于对进行化学疗法的患者进行骨髓保护。